Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of Saxagliptin + Metformin Immediate Release (IR) Versus Metformin IR Alone in Type 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetes~* 18-78 years of age~* Taking stable twice daily (BID) dosing of metformin IR (at least 1500 mg) for at least 8 weeks~* A1C: 7-10%~* C-peptide: ≥ 0.8 ng/mL~* Body mass index (BMI): ≤45 kg/m\^2~Exclusion Criteria:~* Women of childbearing potential unable or unwilling to use acceptable birth control~* Women who are pregnant or breastfeeding~* Fasting plasma glucose (FPG) \>270 mg/dL~* Significant cardiovascular history~* Symptoms of poorly controlled diabetes~* History of diabetic ketoacidosis or hyperosmolar nonketotic coma~* Insulin therapy within one year of screening~* Cardiovascular even within the prior 6 months~* New York Heart Association Stage III/IV congestive heart failure and/or known left ventricular ejection fraction \<=40%~* Significant history of renal or hepatic disease~* History of a psychiatric disorder, alcohol or drug abuse within the previous year~* Treatment with potent CYP3A4 inhibitors or inducers~* Immunocompromised participants~* Active liver disease or clinically significant abnormal hepatic, renal , endocrine, metabolic, or hematological screening tests

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 78 Years
- Healthy Volunteers: f

Study Arms:
- Saxagliptin plus metformin IR (Type: ACTIVE_COMPARATOR): None
- Placebo plus metformin IR (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).